Department of Emergency Medicine, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Department of Emergency Medicine, Jeju National University School of Medicine, Jeju, Republic of Korea.
BMJ Open. 2018 Sep 28;8(9):e020974. doi: 10.1136/bmjopen-2017-020974.
To evaluate whether oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin increase the risk of ventricular arrhythmia in Korea's general population.
Population-based cohort study using administrative claims data on a national scale in Korea.
All primary, secondary and tertiary care settings from 1 January 2015 to 31 December 2015.
Patients who were prescribed the relevant study medications at outpatient visits.
Each patient group that was prescribed ciprofloxacin, levofloxacin, ofloxacin or moxifloxacin was compared with the group that was prescribed cefixime to assess the risk of serious ventricular arrhythmia (ventricular tachycardia, fibrillation, flutter and cardiac arrest). Using logistic regression analysis with inverse probability of treatment weighting using the propensity score, OR and 95% CI for serious ventricular arrhythmia were calculated for days 1-7 and 8-14 after the patients commenced antibiotic use.
During the study period, 4 888 890 patients were prescribed the study medications. They included 1 466 133 ciprofloxacin users, 1 141 961 levofloxacin users, 1 830 786 ofloxacin users, 47 080 moxifloxacin users and 402 930 cefixime users. Between 1 and 7 days after index date, there was no evidence of increased serious ventricular arrhythmia related to the prescription of ciprofloxacin (OR 0.72; 95% CI 0.49 to 1.06) and levofloxacin (OR 0.92; 95% CI 0.66 to 1.29). Ofloxacin had a 59% reduced risk of serious ventricular arrhythmia compared with cefixime during 1-7 days after prescription. Whereas the OR of serious ventricular arrhythmia after the prescription of moxifloxacin was 1.87 (95% CI 1.15 to 3.11) compared with cefixime during 1-7 days after prescription.
During 1-7 days after prescription, ciprofloxacin and levofloxacin were not associated with increased risk and ofloxacin showed reduced risk of serious ventricular arrhythmia. Moxifloxacin increased the risk of serious ventricular arrhythmia.
评估在韩国普通人群中,口服环丙沙星、左氧氟沙星、氧氟沙星和莫西沙星是否会增加室性心律失常的风险。
使用韩国全国范围内的行政索赔数据进行基于人群的队列研究。
2015 年 1 月 1 日至 12 月 31 日期间的所有初级、二级和三级保健机构。
在门诊接受相关研究药物治疗的患者。
将接受环丙沙星、左氧氟沙星、氧氟沙星或莫西沙星治疗的每个患者组与接受头孢克肟治疗的组进行比较,以评估严重室性心律失常(室性心动过速、颤动、扑动和心脏骤停)的风险。使用倾向评分的逆概率治疗加权的逻辑回归分析,计算患者开始使用抗生素后第 1-7 天和第 8-14 天严重室性心律失常的 OR 和 95%CI。
在研究期间,有 4888890 名患者接受了研究药物治疗。其中包括 1466133 名环丙沙星使用者、1141961 名左氧氟沙星使用者、1830786 名氧氟沙星使用者、47080 名莫西沙星使用者和 402930 名头孢克肟使用者。在索引日期后的 1-7 天内,没有证据表明环丙沙星(OR 0.72;95%CI 0.49-1.06)和左氧氟沙星(OR 0.92;95%CI 0.66-1.29)处方与严重室性心律失常风险增加相关。与头孢克肟相比,氧氟沙星在处方后 1-7 天内严重室性心律失常的风险降低了 59%。而莫西沙星在处方后 1-7 天内与头孢克肟相比,严重室性心律失常的 OR 为 1.87(95%CI 1.15-3.11)。
在处方后 1-7 天内,环丙沙星和左氧氟沙星与严重室性心律失常风险增加无关,而氧氟沙星显示出严重室性心律失常风险降低。莫西沙星增加了严重室性心律失常的风险。